You searched for cellectis - Page 12 of 12

News and Trends 22 Jul 2015

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Adaptimmune Therapeutics, an oxford-based company focusing on the use of T-cell therapies to treat cancer, announced today that data from its Phase I/II study in patients with multiple myeloma has been published in Nature Medicine. This is the first report on TCR engineered T-cell therapy that shows durable persistence in patients! After its successful intoduction on […]

July 22, 2015 - 3 minutesmins - By Joachim Eeckhout

eye Bayer Healthcare Johns Hopkins University

News and Trends 9 Jul 2015

Vision specialist Gensight eyes a €90M IPO on NASDAQ

French Gensight intends to raise one of the biggest European IPOs on the American stock market. The gene-therapy specialist will pursue €90.6M to advance with two early-stage candidates for orphan eyes diseases. Gensight will travel across the Ocean to look for the same success its compatriots had on the American stock market. The company will […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 25 Jun 2015

Video: Discover How CAR-T Therapies are Working

It’s becoming a habit for us to talk about CAR-T therapies. It’s basically the next wave of treatments against cancer and already promises to be the future blockbusters and growth drivers of the whole Biotech industry. Cellectis, a leading company in this field, just published a cool video about CAR-Ts. Of course, they’re describing more specifically their own therapy, […]

June 25, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 22 Jun 2015

American Companies are Invading London’s Biotech Stock Market

[Update: On June 19, Puretech successfully raised $171M – approximately €150M – during its IPO, setting its market cap at €509M] Boston-based PureTech Health plans to raise €147M on the London stock market, following the path of Verseon, a San Diego-based bioinformatic company that raised €92M earlier this month. Is there a new American trend to earn cash in […]

June 22, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 18 Jun 2015

German Viral Vector Producer SIRION pursues its American dream and opens in Boston

The biggest biocluster of the World is still attractive. Munich-based Sirion Biotech decided to open an office to establish its US presence and benefit from Boston’s leading position in the gene therapy field. Gene Therapy is the next big thing in Biotech and is now moving from a theoretical dream to reality. Boston is clearly the hotspot for […]

June 18, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Jun 2015

Pieris Pharma: is it worth going to NASDAQ for only €31 Million?

Pieris Pharmaceutical is planning to raise €31M in an surprisingly low US IPO. The company seeks to advance its early-stage pipeline with a special focus on its anemia treatment, Pieris’s most advanced candidate which recently completed the enrollment of its Phase I. Pieris’ pipeline might be premature, but it is ambitious. The company’s focus includes […]

June 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 20 May 2015

[UPDATE] Galapagos with €277.3M, made the Biggest European Biotech IPO ever on NASDAQ

[UPDATE 20/05/2015]: Galapagos announced the closing of its NASDAQ IPO, where the company raised a total of €277.3M. Galapagos has once again made the front page thanks to its unbeaten IPO. The company just raised €240M on Nasdaq, becoming the biggest European biotech IPO ever on the US stock market. The Belgium company just ranked […]

May 20, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 6 Apr 2015

Gene editing to make French fries less unhealthy

A promising biotechnological approach or an innovative way of avoiding regulation? Large companies spend an average of €126M on the development of a genetically engineered crop (GMO), including €32M in regulatory costs. The Agriculture Department once takes two to five years to review applications, though it is trying to reduce that to 13 to 16 […]

April 6, 2015 - 4 minutesmins - By Cédric Brock

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us